On Jul. 27, 2021, Oragenics announced it had entered into a licensing agreement with the National Research Council of Canada (NRC) that enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

The NRC technologies, in combination with the U.S. National Institutes of Health (NIH) elements found in the Companyﾒs Terra CoV-2 vaccine, provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines.